Thus, it seems critical to include obese cancer patients in TGF-β blockade clinical trials in order to dissect the impact of obesity-associated TGF-β1 signaling on immunotherapy response. This evidence concerns the gene TGFB1 and obesity due to melanocortin 4 receptor deficiency.